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Abstract
Recent years have seen an increasing number of genetically engineered pig models of human diseases including cancer.
We previously generated pigs with a modified TP53 allele that carries a Cre-removable transcriptional stop signal in intron 1,
and an oncogenic mutation TP53R167H (orthologous to human TP53R175H) in exon 5. Pigs with the unrecombined mutant
allele (flTP53R167H) develop mainly osteosarcoma but also nephroblastomas and lymphomas. This observation suggested
that TP53 gene dysfunction is itself the key initiator of bone tumorigenesis, but raises the question which aspects of the TP53
regulation lead to the development of such a narrow tumour spectrum. Molecular analysis of p53 revealed the presence of
two internal TP53 promoters (Pint and P2) equivalent to those found in human. Consequently, both pig and human express
TP53 isoforms. Data presented here strongly suggest that P2-driven expression of the mutant R167H-Δ152p53 isoform
(equivalent to the human R175H-Δ160p53 isoform) and its circular counterpart circTP53 determine the tumour spectrum
and play a critical role in the malignant transformation in flTP53R167H pigs. The detection of Δ152p53 isoform mRNA in
serum is indicative of tumorigenesis. Furthermore, we showed a tissue-specific p53-dependent deregulation of the p63 and
p73 isoforms in these tumours. This study highlights important species-specific differences in the transcriptional regulation
of TP53. Considering the similarities of TP53 regulation between pig and human, these observations provide useful pointers
for further investigation into isoform function including the novel circTP53 in both the pig model and human patients.
Introduction
In human, osteosarcomas (OS) is the major form of primary
bone cancer [1]. It predominantly affects young people and is
highly malignant, requiring aggressive surgical resection and
cytotoxic chemotherapy [2]. The 5-year survival rate has
remained unchanged over the past 20 years, at ~60% for
patients with primary osteosarcoma and ~20% for patients with
metastatic disease [3]. Most OS are sporadic and of unknown
cause, but increased incidence is associated with Li–Fraumeni
syndrome caused by germ line mutation of TP53 [4, 5].
The role of TP53 mutations in numerous cancers has been
extensively documented [6]. Yet, potentially important aspects
of TP53 gene function still remain unclear, including the role
of various p53 isoforms. Human TP53 is known to express at
least 9 different mRNA transcripts [7] and at least 12 protein
isoforms [8], with transcription initiated by two promoters: P1
at the 5’ end and P2 in intron 4; alternative splicing across
introns 2 and 9; and alternative translation initiated at internal
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start codons 40, 133 and 160. The internal promoter P2 ori-
ginates the Δ133p53 and Δ160p53 isoforms in humans.
While the function of Δ160p53 is less studied, the Δ133p53 is
involved in the regulation of replicative cellular senescence
[9], angiogenesis, cytokine secretion/immune response and
tumour progression in some cancer types [10].
Pigs have become an important animal model for human
cancers research, translational studies and preclinical trials
[11, 12]. We have generated genetically engineered (GE) pigs
with mutations in key tumour suppressor genes and proto-
oncogenes [13] to facilitate preclinical studies [14]. As part of
this programme we generated pigs modelled on GE mice
carrying a Cre-inducible oncogenic mutant Trp53R172H allele,
in which a floxed transcriptional stop cassette is inserted into
Trp53 intron 1 to block transcription of the mutated allele
[15]. The latent allele can be experimentally activated by Cre
recombinase to express mutant p53R172H and model sponta-
neous somatic Trp53 mutation in chosen organs. These mice
have been used successfully to model a series of cancers, e.g.,
pancreatic, breast and lung [16–19]. Similarly, our pig line
carries an engineered endogenous TP53 gene with a floxed
transcriptional stop signal in intron 1 and a point mutation
resulting in an arginine to histidine substitution at codon 167
in exon 5 (TP53R167H, orthologous to mouse Trp53R172H and
human TP53R175H) [20]. As this pig line was being established
it became apparent that animals with the latent non-induced
allele (designated here as flTP53R167H) in both heterozygous
and homozygous form developed OS [21] and less frequently
kidney tumours and lymphomas.
This phenotype contrasts sharply with that reported for
mice carrying the apparently equivalent non-induced
Trp53R172H allele, which mostly develop lymphoma [22].
None of the murine Trp53 mutant strains so far generated
show a preponderance of OS in the tumour spectrum
[22, 23]. These include Cre-inducible point mutations [23],
partial deletions of the Trp53 coding region [15] and
transgenic lines that overexpress mutant Trp53R270H and
Trp53R172H from exogenous promoters [24]. To increase the
incidence of OS, several mouse strains expressing osteo-
blast- and mesenchymal-specific Cre coupled with condi-
tional p53 and Rb1 mutant alleles were generated [25].
These findings indicate a species-specific difference in
p53 gene regulation. Differences in the p53 isoforms and
internal promoters have been described for humans, primates,
zebrafish, drosophila and mouse [8]. Here we show that
unlike the mouse, the porcine TP53 locus contains internal
Pint and P2 promoters equivalent to those found in human,
resulting in expression of Δ152p53α isoform and its circular
counterpart circTP53. Both are involved in the development
of OS and others tumours in the flTP53R167H pigs and the
detection of Δ152p53α isoform in serum is indicative of
tumorigenesis. A tissue-specific p53-dependent deregulation
of p63 and p73 isoforms could be observed in these tumours.
Results
Cancer spectrum in flTP53R167H pigs
Since our publication describing the generation of
flTP53R167H pigs [20], a total of 29 flTP53R167H/+ hetero-
zygous and 10 flTP53R167H/R167H homozygous pigs were
examined by necropsy. All had reached sexual maturity.
Animals were sacrificed as soon as they showed symptoms
effecting their wellbeing or in case of the heterozygous
animals latest at the age of 36 months. By this time 18 of the
29 heterozygous animals had developed tumours, all of
which were classified histologically as osteoblastic OS.
Spontaneous OS is very rare in wild-type pigs [21, 26]. All
homozygous pigs had OS by the age of 16 months or earlier
and five of these (aged 7–14 months) also had nephro-
blastoma (kidney) and diffuse large B-cell lymphomas
(spleen). In each case the anatomical location and histolo-
gical analyses of the tumours resembled those of the human
juvenile cancer.
Identification of a Δ152p53α isoform in pigs
The observation that the tumour repertoire was restricted to
a few tissue types (100% OS, 22% nephroblastoma and
17% B-cell lymphomas) leads to the question which aspects
of TP53 expression or absence thereof support the forma-
tion of mainly OS rather than other tumour entities?
To answer this question, we first establish if expression of
the floxed flTP53R167H allele was silenced in all organs.
A series of RT-PCR primers hybridising to different por-
cine TP53 exons (Fig. 1a) were used to screen RNA samples
from various organs (n= 11) of flTP53R167H/R167H homo-
zygous pigs (n= 3). No mRNA expression was detected
using RT-PCR primers specific for exon 1 to exon 2 (1F/1R),
or exon 2 to 4 (2F/2R) in all tissues analysed including bone
and OS samples (Fig. 1b), confirming that the LSL efficiently
blocked transcription. However, RT-PCR using primers
between exons 5 and 11 (5F/9R, see Fig. 1a) revealed a tissue-
specific expression (Fig. 1c), where the strongest RT-PCR
signal was obtained for bone, lymph node and kidney tissues.
This indicated the presence of a promoter element in intron
4 similar to human. No expression of the short TP53 mRNA
was detected in heart and aorta. To determine the start and
termination of the porcine TP53 isoform 5’ and 3’ rapid
amplification of cDNA end (RACE) analysis was performed
(Fig. 1d, e). This placed the start of the isoform 11 base pairs
upstream of exon 5 with a possible ATG at amino acid
position 152 (Δ152p53 isoform), which translates in frame
and terminates at the same stop codon as the full length p53
and corresponds to TP53α isoform (Supplementary Fig. 1).
The identified Δ152p53α mRNA has a length of 1295 bp; the
nucleotide sequence was verified by sequencing.
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Expression of Δ152p53α isoform is highest in organs
susceptible to cancer development
By using primers (9F/6R) specific for the Δ152p53α iso-
form its expression was quantified by qPCR in different
healthy tissues (n= 11) from flTP53R167H homozygous
(n= 10) and wild-type (n= 3) pigs. The highest Δ152p53α
mRNA expression in flTP53R167H homozygous pigs was
observed in lymph nodes, spleen, kidney and bone (Fig. 1f),
all organs prone to tumour development in mutant pigs.
Except for lymph node, colon and small intestine the
Δ152p53α mRNA expression was generally lower in wild-
type samples, than in flTP53R167H homozygous samples.
The porcine Δ152p53α isoform encodes a 30kDa
protein
The methionine codon 152 in pigs corresponds to codon 160
in human p53, which is located within a highly conserved
Kozak sequence [27]. An in silico analysis predicted that the
1295 bp mRNA encodes a 224 amino acid N-terminal-
truncated Δ152p53α isoform using the same reading frame
as full length p53. The predicted porcine isoform shares 88%
amino acid sequence homology with the human Δ160p53α
isoform, which uses the Δ133/160p53 alternative transcrip-
tional initiation site in exon 5 [27] and contains part of the
highly conserved p53 DNA binding region [8]. To determine
whether the porcine TP53 alternative transcript can produce
Δ152p53α protein, western blot analysis of different healthy
tissue samples from flTP53R167H/R167H homozygous pigs was
performed using the polyclonal sheep SAPU antibody
recognising all human p53 isoforms. Two bands (doublet) of
~30 kD were detected (Fig. 1g). As with the mRNA highest
protein expression was observed in bone, kidney, lymph
node and spleen. The size of the western blot bands was
comparable to the human Δ160p53 isoforms [27], and most
likely represent splice variant or post-translational modifica-
tions of R167H-Δ152p53 proteins.
Identification of internal promoters in the porcine
TP53
Results above clearly indicated the presence of at least one
internal promoter. To determine the location of all possible
internal promoters, nucleotide sequence alignment was carried
out between the porcine (NC_010454, GenBank Sscrofa 11.1)
Fig. 1 Identification of Δ152p53α isoform in pigs. a Schematic
representation of the TP53 gene and the Δ152p53α mRNA.
b Expression analysis across exon 1 to 2 (186 bp), exon 2 to 4 (591 bp)
of bone samples from wild-type pigs and healthy bone and OS sam-
ples from flTP53R167H/R167H pigs showing lack of expression for mutant
TP53. c Expression analysis across exon 5 to 11 (492 bp) for 11
different organ samples from flTP53R167H/R167H pigs. d 5’ RACE using
a reverse primer hybridising to exon 6 of TP53 and resulting in a
237 bp fragment and e 3’ RACE using forward primer hybridising to
exon 11 of TP53 resulting in a 511 bp fragment. Healthy bone (b),
kidney (k) and osteosarcoma (OS) samples from flTP53R167H/R167H
pigs. M marker, nc negative control. f Quantitative RT-PCR analysis
using primers hybridising to extended exon 5 and exon 6 and detecting
the Δ152p53 isoform mRNA expression in different tissues of
flTP5R167H/R167H (n= 6) and wild-type (n= 3) pigs. GAPDH was used
as a reference gene to calculate the relative expression levels.
g Detection of Δ152p53 isoform by western blot analysis using SAPU
antibody in different tissues from flTP5R167H/R167H pigs.
Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA
and human (NC_000017, Genbank GRCh38.p12) TP53 gene.
Apart of exons, three genomic regions with high homology
(>70% similarity) were detected (–1877 to +11 bp, +2125 to
+3200 bp and +9985 to +10,470 bp; relative to the major
transcription start site). These porcine TP53 regions corre-
spond to the locations of the P1 (5’end), Pint (intron 1) and P2
(intron 4) promoters in human TP53. As for the human
sequence, the porcine intron 4 sequence (P2) contains binding
sites for the transcription factors NFIC, Hltf and SPI1. In
contrast, the sequence of mouse Trp53 intron 4 showed less
than 50% homology to human TP53, and lacks binding sites
for these transcription factors (Supplementary Fig. 2). Inter-
estingly, the NFIC transcription factor regulates osteoblast
differentiation [28], and can promote or suppress the devel-
opment of various cancers [29] via epigenetic changes [30].
The SPI1 transcription factor regulates alternative transcription
of target genes, and both Hltf and SPI1 are frequently mutated
in paediatric cancers [31, 32].
To confirm promoter function five luciferase reporter
constructs were generated containing the P1 promoter
(−2000 bp to TSS), the putative P2 promoter (intron 4) and
three different fragments covering the first intron (Pint_1,
Pint_2, Pint_3), see Fig. 2a. Luciferase expression driven by
the SV40 promoter was used as positive control.
Luciferase activity was measured after transfection of var-
ious porcine primary cells: wild-type bone marrow mesench-
ymal stem cells (bmMSC) and kidney fibroblasts; flTP53R167H/
R167H OS cells and healthy osteoblasts; and human HEK293
cells. In comparison to the positive control two of the putative
promoter fragments led to moderate (P1, 40–70% and Pint_1,
30–45%) and one to low (P2, 10–25%) luciferase activity
(Fig. 2a). These three promoter fragments shared the greatest
homology with the corresponding human TP53 sequence. The
in silico and experimental data provide evidence for the pre-
sence of internal promoters within intron 1 (Pint) and intron 4
(P2) of the porcine TP53, similar to those in human TP53.
Expression from the P1 and Pint promoters is blocked by
lox-stop-lox cassette in flTP53R167H homozygous pigs. Addi-
tional deletion of the P2 promoter fragment should result in a
complete inactivation of porcine TP53. Using the Crispr-Cas9
system and two guide RNAs a DNA fragment from 9665 to
10,374 bp of pig TP53 (NC_010454) was excised in OS cells
from flTP53R167H homozygous pigs (Supplementary Fig. 3a).
RT-PCR analysis showed no TP53 expression in the edited
porcine OS cells (Supplementary Fig. 3b), confirming that the
P2 promoter is responsible for the Δ152p53α expression.
The R167H-Δ152p53α isoform is overexpressed in
tumours
To assess the RNA and protein expression of Δ152p53α
isoform in cancer, we analysed tumours collected from
flTP53R167H pigs. Quantitative PCR and western blot revealed
more than three-fold (P < 0.001) higher expression of R167H-
Δ152p53α isoform in OS compared to matched healthy bones
(Fig. 2b–d). The level of Δ152p53α mRNA expression
increased (P= 1.17 × 10–5) with OS tumour size (Fig. 2e).
The expression level of the Δ152p53α mRNA in healthy
bones correlated with the onset of cancer clinical symptoms
in homozygous flTP53R167H pigs (Fig. 2f). The higher
R167H-Δ152p53α was expressed the earlier tumours
became evident. In wild-type pigs the level of Δ152p53α
expression remained unchanged with age (Fig. 2f).
The above results hinted that overexpression of the
mutant R167H-Δ152p53α isoform was essential for
tumorigenesis. To assess if this also applied to other tumour
types samples from the nephroblastomas and B-cell lym-
phomas were analysed. As for the OS, an overexpression of
Δ152p53α isoform was observed in kidney and spleen
tumours (Fig. 2g). Finally, we also tested if the orthologous
Δ133/160p53 mRNA was expressed in human OS samples.
These too were positive (Supplementary Fig. 4).
Overexpression of the Δ152p53α isoform seemed essential
for tumour growth. To confirm this, and to assess if the effect
was due to the expression of the wild-type or mutant isoform, a
proliferation assay was performed. Pig OS cells transfected
with an expression vector carrying the wild-type Δ152p53α or
mutant R167H Δ152p53α cDNA sequence under the control
of the CAG promoter showed significantly increased pro-
liferation compared to those transfected with control GFP
vector (Supplementary Fig. 5). The highest proliferative
increase was obtained for the mutant isoform. Next, we tested if
expression of the mutant R167H Δ152p53α isoform also
increases cell migration and invasion. Compared to the control
a significant difference was observed (Fig. 2i).
The MDM2 oncoprotein is a key regulator of p53
expression, which is stabilised by mutant p53 [33]. To
determine if the mutant Δ152p53α protein isoform retains this
function, western blot analysis was carried out and showed an
increased MDM2 protein expression in OS tumour samples
(Fig. 2c). Taken together, these data indicate that the mutant
Δ152p53α isoform plays a critical role in the malignant
transformation of bones, kidney or spleen in flTP53R167H pigs.
Blood exosomal Δ152p53α expression is indicative
of tumorigenesis
In order to investigate whether the increased expression of
R167H-Δ152p53α mRNA during malignancy can be
detected in serum samples and used as a biomarker, exo-
somes were isolated from flTP53R167H heterozygous (n= 6),
homozygous (n= 6) and wild-type (n= 3) pigs aged 3 and
10 months. At the age of 3 months all animals were disease
free while at the age of 10 months the flTP53R167H homo-
zygous pigs showed first signs of cancer, confirmed later by
necropsy. QPCR showed a six-fold higher level (P < 0.01)
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of R167H-Δ152p53α mRNA in exosomes from 10-month
old flTP53R167H homozygous pigs than from the same pigs
at the age of 3 months (Fig. 2h). The exosomal Δ152p53
mRNA expression in flTP53R167H heterozygous and wild-
type pigs was low and unchanged over the same time period
(Fig. 2h). These data suggest that detection of Δ152p53α
isoform mRNA in serum is indicative of tumorigenesis.
The DNA methylation in the P2 promoter is
negatively correlated with the mutant Δ152p53α
expression in OS cells and tumours
The P2 promoter showed an increased activity in tumours.
It has been reported that intragenic TP53 methylation differs
between normal and transformed human colorectal cancer
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cell lines [34]. To evaluate if epigenetic changes correlate
with altered expression levels a comparison of the DNA
methylation in healthy osteoblasts and OS cells derived
from flTP53R167H/R167H pigs was carried out. CpG regions in
the P1 promoter, intron 1 (fragments Pint_1, Pint_2,
Pint_3), P2 promoter and exon 5 were identified. DNA
methylation at four or more CpG sites was analysed for
each region. Overall, CpG methylation was higher in the
gene body than in the P1 promoter (Fig. 3a), which is
consistent with TP53 methylation pattern in human [35].
The highest DNA methylation (>80%) was observed in
Pint_2 and Pint_3 fragments that showed no promoter
activity. The genomic regions of P1, Pint_1 and P2 pro-
moters showed 18%, 28%, and 64% DNA methylation in
healthy osteoblasts, respectively. The DNA methylation at
five CpG sites in Pint_1, P2 and exon 5 was significantly
lower in OS than in healthy osteoblasts cells (Fig. 3a). The
level of DNA methylation in osteoblasts and OS cells
inversely correlated with promoter activity (Fig. 3b).
The same analysis was carried out for OS tissue samples.
Compared to healthy bone the same five CpG sites as
mentioned above showed significantly reduced DNA
methylation in OS. The level of DNA methylation was as
follows: in Pint_1—CpG3 (41% vs. 22%, healthy bone vs.
OS, P < 0.01), in the P2 promoter—CpG2 (99% vs. 62%,
P < 0.0001) and CpG3 (96% vs. 65%, P < 0.0001) site, and
CpG5 (94% vs. 63%, P < 0.01) and CpG6 (67% vs. 52%,
P < 0.01) site within the Kozak sequence (Fig. 3c and
Supplementary Fig. 6e). CpGs in this region have been
shown to be differentially methylated for the Δ133/160
isoforms in human [34]. The regression analysis revealed
that the decreased methylation at CpG2 and CpG3 sites in
the P2 promoter is correlated with higher R167H-
Δ152p53α mRNA expression in OS (P= 2.9 × 0−7;
Fig. 3d).
TP53 circular RNA enhances proliferation of OS cells
There is increasing evidence that circular RNAs (circRNAs)
play a role in human cancer [36, 37], but so far no data have
been reported showing expression of a circRNA for TP53
(circTP53). To identify circTP53 in flTP53R167H/R167H,
several pairs of divergent primers were designed for RT-
PCR analysis resulting in the detection of four different
circTP53 in flTP53R167H/R167H tissues (circTP53-1 to -4,
Fig. 4a), of which circTP53-3 was highly expressed in bone.
All were expressed from the P2 promoter and encoded
within the Δ152p53α isoform, which was confirmed by
Sanger sequencing and RNase R digestion (Fig. 4b). RT-
PCR analysis revealed a tissue-specific expression of
circTP53 variants, with their highest expression in bone,
kidney and colon (Fig. 4c). No expression of circTP53 was
found in heart and aorta, which is consistent with the lack of
Δ152p53α expression in these organs. Compared to healthy
bones, the circTP53 expression was significantly increased
(P < 0.001) in OS (Fig. 4d, e).
To test, whether the newly detected circTP53 has any
effect on cell proliferation, an overexpression vector, con-
sisting of exon 5 to exon 9 (circTP53-3) and the R167H
mutation under the control of CMV promoter, was gener-
ated. As shown in Fig. 4f, the proliferation of pig OS cells
overexpressing the circTP53 was significantly increased
(P < 0.001) compared to cells transfected with a control
GFP vector.
Altered expression of p63 and p73 in tumours from
flTP53R167H pigs
The p53 family includes two other members: p63 and p73,
all three genes are structurally similar, and have been
implicated in cell regulation and cancer [38, 39]. This raised
the question whether the TP53 mutation also influenced the
expression of p63 and p73 in flTP53R167H pigs.
p63
p63 has two major isoforms, TAp63 and ΔNp63, which
have different roles in tumorigenesis. While ΔNp63
isoform promotes, the TAp63 suppresses tumour growth
in mice [40]. Different tissues (n= 11) from flTP53R167H
homozygous (n= 10) and wild-type (n= 3) pigs were
analysed by qPCR with primers located in exon 3 and
Fig. 2 Identification of porcine TP53 promoters and expression of
Δ152p53α isoform in osteosarcomas. a Dual-luciferase assay: luci-
ferase was expressed from the SV40 promoter and used to normalise
the Renilla expression under the control of the putative promoter
fragments. Their location relative to the gene structure is depicted.
Values represent mean ± standard deviation, six transfections per
construct. Promoterless luciferase vector was used as a negative con-
trol. bmMSC bone marrow mesenchymal stem cells, osb porcine
flTP53R167H/R167H osteoblasts, OS porcine flTP53R167H/R167H osteo-
sarcoma cells, KDNF porcine kidney fibroblasts, HEK293 human
embryonic kidney cell line. b Quantitative PCR results of Δ152p53α
mRNA expression in OS (n= 48) and matched healthy bone samples.
c Representative western blots showing Δ152p53α protein and MDM2
expression in OS and healthy matched bone samples of homozygous
flTP53R167H pigs. d Quantitative measurements of proteins in OS (n=
10) and healthy matched bone samples from homozygous flTP53R167H
pigs. e The Δ152p53α mRNA expression in small (<5 cm, n= 29) vs.
large (>5 cm, n= 19) tumours. f Age-dependent Δ152p53α mRNA
expression in healthy bones of homozygous flTP53R167H (n= 10) and
wild-type (n= 3) pigs. g Western blots showing Δ152p53α isoform
expression kidney and spleen tumours and healthy matched tissues of
flTP5R167H/R167H pigs. h QPCR analysis of Δ152p53α mRNA expres-
sion in blood exosomes from flTP53R167H heterozygous (n= 6),
homozygous (n= 6) and wild-type (n= 3) pigs aged 3 and 10 months.
i Migration and invasion Transwell assays for pig OS cells transfected
with mutant R167H Δ152p53α isoform or a GFP control vector. Left,
representative microscopic image (scale bars, 200 μm). Right, quanti-
fication of the indicated migrated and invaded cells numbers.
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exon 4. The expression of the detected TP63 mRNA
variant was significantly lower in heart, lung, bones and
higher in lymph node, colon, spleen in flTP53R167H
homozygous compared to wild-type pig tissues (Fig. 5a).
Western blot analysis revealed tissue-specific expression
of two TAp63 isoforms, TAp63α and TAp63δ and no
expression of ΔNp63 (Fig. 5b). While the TAp63α iso-
form was highly expressed in wild-type kidney, the
TAp63δ showed an overexpression in wild-type bones,
and kidney and spleen tumours (Fig. 5c), and variable
expression in OS (Fig. 5d) from flTP53R167H pigs, indi-
cating that the TP53 mutation has a tissue- and tumour-
specific effect on the TAp63δ isoform expression.
p73
In humans, p73 has two different promoters, which regulate
several isoforms: full length TAp73 and N-terminal trun-
cated ΔNp73, which can be distinguished by their transac-
tivation functions [41, 42]. It has been suggested that
TAp73 has a tumour suppressor function similar to that of
p53, whereas ΔNp73 isoforms would promote cell growth
by regulating activities of p53 family members [43]. QPCR
analysis revealed a high TP73 mRNA expression in kidney,
lung, liver, colon, spleen, bone, lymph node and no
expression in muscle and brain of wild-type animals
(Fig. 6a). It was significantly lower in colon and small
intestine but higher in lung, bone, spleen of flTP53R167H
homozygous pigs compared to wild-type (Fig. 6a). Western
blot detected the TAp73α isoform in kidney and liver and
the TAp73δ isoforms in spleen, liver, lung of flTP53R167H
homozygous and wild-type pigs (Fig. 6b). Compared to
wild-type, an overexpression of TAp73δ isoform was
observed in healthy bones (Fig. 6b) and tumours (Fig. 6c, d)
from flTP53R167H homozygous pigs.
We next determined if the p73 isoforms expression is
correlated with DNA methylation in the two promoter
regions. A hypermethylation of the ΔNp73 promoter and a
hypomethylation of the TAp73 promoter was observed.
The DNA methylation at all five CpG sites of TAp73
promoter differed significantly, in particular at CpG1 (21%
vs. 9%, P < 0.001) between OS and matched healthy bone
samples (Fig. 6f), which suggests that the CpG sites may
be involved in the regulation of the TAp73 isoform
expression.
To further investigate the function of p73 in tumor-
igenesis, a porcine TP73 full length cDNA expression
vector, containing both the TAp73 and ΔNp73 translation
start codons, was transfected into porcine OS and human
OS (SAOS2) cells. The TP73-transfected cells showed an
overexpression of the TAp73δ, no expression of ΔNp73
isoform (Fig. 6e) and significantly (P < 0.01) increased
growth rate compared to the GFP transfected control
cells. These data indicated that the TAp73δ isoform is
Fig. 3 DNA methylation level
of porcine TP53 promoters.
a DNA methylation analysis of
CpGs located in putative
promoter regions in TP53 in
osteoblasts and OS cells of
flTP53R167H/R167H pigs. b The
correlation plot for promoter
activity and DNA methylation.
The values on the plot are
aligned to the TP53 gene
structure. c Pyrosequencing
analysis of four CpG sites in P2
promoter (P2 fragment) in OS
(n= 48) and matched healthy
bone (n= 29) of flTP53R167H
pigs. Values shown represent
mean ± SD. **P < 0.01, ***P <
0.001. d Regression analysis
between CpG methylation at site
2 in P2 promoter and Δ152p53α
mRNA expression in OS (y=
12.81–0.12, P= 2.9 × 10–7).
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predominantly translated from the TP73 cDNA and has an
effect on the proliferation of these cells.
In summary, these analyses showed for the first time the
expression of p63 and p73 isoforms in porcine tissues and
the upregulation of the two isoforms (TAp63 and TAp73)
presumed to have tumour suppressor function in porcine
tumours. However, overexpression of TAp73δ did not lead
to a reduction but to an increase in cell proliferation, which
may confirm that different C-terminal variants may lack
growth suppressing function.
Discussion
It is becoming evident that p53 isoforms, including those
derived from the internal P2 promoter, have implications in
human cancers [8]. Further elucidation of their roles,
interactions, regulation and patterns of expression could
open novel approaches for the prognosis and treatment of
cancer. But the study of p53 isoforms and its involvement in
tumorigenesis had been hampered by the fact that the main
experimental mammal, the mouse, lacks internal P2 pro-
moter activity [8]. This motivated the generation of
mice that ubiquitously express a Δ133p53-like protein
(Δ122p53) through deletion of exon 3 and 4 [44, 45].
Homozygous Δ122p53 mice show an enhanced proin-
flammatory phenotype and are prone to develop B-cell
tumours [46] with low incidence of OS (17%) [45].
Although this mouse model does not replicate the situation
in human, its strongly supports the notion that p53 isoforms
play a role in cancer.
The study presented here shows that the porcine TP53—
unlike the mouse—has two internal promoters, Pint in
intron 1 and P2 in intron 4. In humans the expression from
the P2 promoter results in two isoforms, Δ160p53 and
Δ133p53. The porcine Δ152p53 protein isoform is
Fig. 4 Identification of





results showing the effect of
RNAase R digestion. c RT-PCR
analysis of circTP53 in different
tissues in flTP5R167H/R167H pigs.
d RT-PCR amplification
showing the effect of RNase R
digestion on circTP53 and
GAPDH amplification.
e Relative expression of
circTP53 in healthy bones and
OS. In parenthesis the number of
circTP53 positive to analysed
samples is shown. f Proliferation
assay in pig flTP53R167H/R167H
OS cells transfected with
circTP53 overexpression vector,
consisting of exon 5 to exon 9
(circTP53-3) under the control
of CMV promoter.
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equivalent to human Δ160p53. The pig lacks the tran-
scription initiation site, which in humans enables translation
of the Δ133p53 protein isoform. Three N-terminal variants
have been observed in humans (p53α,β,χ). The porcine
mRNA isolated by RT-PCR represents the Δ152p53α
mRNA. However, western blot analysis indicated that
N-terminal variants are present in the pig.
To our best knowledge this is the first report showing an
association between P2 promoter activity and epigenetic
modifications in normal and tumour tissue. This is an
important finding as epigenetic modulation has been sug-
gested as a means of restoring wild-type p53 function, or
inactivating mutant p53 activity in human cancer [47].
Comparison with human data shows that the porcine
Δ152p53α mRNA is expressed in a similar tissue-specific
manner, including high expression, e.g., in bone and lack
of expression in heart tissue [7]. Our study strongly sug-
gests that the predominance of OS followed by nephro-
blastomas and B-cell lymphomas in pigs carrying the
floxed TP53R167H allele is related to the higher level of
Δ152p53α expression in these organs. This is further
supported by the finding that pigs with early onset of OS
have also higher expression of the Δ152p53α isoform in
healthy bone tissue.
Expression of Δ152p53α isoform increases during
tumorigenesis, which is consistent with the expression of p53
isoforms in human cancers [48]. The overexpression of
Δ133/Δ160p53 variants and their potential oncogenic func-
tion have been reported in lung, colon, breast and ovarian
cancers and in melanoma [49–52]. In the pig, an over-
expression of the wild-type and mutant R167HΔ152p53α
isoform enhanced cell proliferation, finding consistent with
data for mutant Δ160p53 isoform in human cancer cells [53].
It was more pronounced for mutant isoform, which would
imply that the tissue-specific expression of the mutant
Δ152p53α isoform drives tumorigenesis in our pig model
and is an indicative blood biomarker.
TP53R167H Yucatan minipig model generated by Sieren
et al. [54] develops a similar tumour spectrum, but the role
of the Δ152p53 in this model is unknown. It is questionable
if the P2 promoter is functional in this model due to the
insertion of a selectable marker gene in intron 4.
It has been suggested that one of the key mechanisms for
p53 gain of function mutations is its interaction with p63/
p73 [55, 56], and that the ratio of TA/ΔNp63/p73 isoforms
determines their effect on tumorigenesis [57, 58]. We
observed an upregulation of the TAp63δ and TAp73δ
isoforms in all studied tumours, and proved that experi-
mental overexpression of the TAp73δ isoform increased
proliferation of human and porcine OS cells. Further
research is required to prove a direct interaction between
the specific isoforms.
Fig. 5 Expression of p63 in flTP53R167H pigs. a Quantitative RT-PCR
analysis of different tissues (n= 11) from flTP5R167H/R167H (n= 6) and
wild-type (n= 3) pigs. b Representative western blots showing p63
protein expression in different tissues of flTP5R167H/R167H and wild-type
pigs. c Western blots showing p63 isoforms expression in healthy and
tumour tissues of kidney and spleen of flTP5R167H/R167H and wild-type
pigs. d Quantitative PCR results of p63 mRNA expression in OS (n=
48) and matched healthy bone samples. e Representative western blots
showing p63 protein expression in OS and healthy matched bone
samples of homozygous flTP53R167H pigs. Quantitative measurements
of protein in OS (n= 10) and matched healthy bone samples of
homozygous flTP53R167H pigs.
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We present the first description of circTP53 RNAs
expressed from the P2 promoter. As with the parental
Δ152p53α isoform it is upregulated in tumours such as OS.
Importantly, the functional study demonstrated that high
circTP53 expression increases cellular proliferation of OS cells.
Similar mechanisms for gene overexpression and upregulation
Fig. 6 Expression of p73 in flTP53R167H pigs. a Quantitative RT-PCR
analysis of p73 mRNA expression in different tissues (n= 11) of
flTP5R167H/R167H (n= 6) and wild-type (n= 3) pigs. b Western blots
showing the tissue-specific p73 isoforms expression in flTP5R167H/R167H
and wild-type pigs. c Western blots showing p73 isoforms and MDM2
proteins expression in bone, kidney and spleen tumours and healthy
matched tissues of flTP5R167H/R167H and wild-type pigs. d Quantitative
PCR (left) and western blot (right) measurements showing p73
expression in OS (n= 48) and matched healthy bone samples.
Representative western blots (bottom) showing TAp73δ isoform
expression in OS and matched healthy bone samples of homozygous
flTP53R167H pigs. Quantitative measurement of western blots was
performed for OS (n= 10) and matched healthy bone (n= 10) samples
of homozygous flTP53R167H pigs. e Proliferation assay in human
SAOS2 (left) and pig flTP53R167H/R167H OS (middle) cells. Western
blot (right) showing the upregulation of the TAp73δ isoform in pig OS
cells transfected with a full length of TP73 cDNA vector. The bar plot
above shows the quantitative protein measurements (n= 3) of western
blots. f DNA methylation analysis of P1 and P2 promotor regions of
TP73 in OS (n= 48) and matched healthy bone samples of
flTP53R167H pigs. Open and filled circles on the TP73 gene structure
indicate unmethylated and methylated DNA regions.
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of circRNA was described for other genes, e.g., androgen
receptor in prostate cancer [59]. The mechanism how circTP53
affects cell proliferation still needs to be elucidated.
Conclusion
The biology of p53 has been studied extensively for 4
decades and still novel insights are being gained. A cross-
species comparison might help to understand the tissue-
specific regulation of TP53. Our study has highlighted the
value of using the pig model. We show that the Δ152p53
isoform, its circular counterpart and the p53 family mem-
bers, TAp63δ and TAp73δ, likely play a role in the malig-
nant transformation of bone and other tumours. Considering
the similarities of TP53 regulation between pig and human,
the observations presented here provide useful information
for further studies on the regulation of p53 in humans.
Material and methods
Animals
Three wild-type, ten (8 males and 2 females) flTP53LSLR167H/
R167H and 24 (13 males and 11 females) flTP53LSLR167H/+
pigs aged 7–32 months were produced by normal breeding
and raised in our animal husbandry facilities with food and
water provided ad libitum.
Necropsy examination and tumour analysis
In total, 51 pigs were euthanised and examined by complete
necropsy (without randomisation). Three bone samples
from wild-type and 48 OS samples with matched healthy
bones from hetero- and homozygous flTP53LSLR167H pigs
were collected and all samples were included in the ana-
lysis. The study was non-blinded.
Porcine primary cells
Porcine bmMSC and kidney fibroblasts were derived in-
house and cultured by standard procedures [20]. All cell
cultures were routinely tested for mycoplasma.
Primers
All primers used are shown in Supplementary Table S1.
For quantitative PCR, 5’ and 3’RACE analysis, RNase
R digestion, pyrosequencing, functional assays, western
blot and sgRNA constructs details see Supplementary text.
Unprocessed western blots are shown in Supplementary
Fig. 7.
Data availability
All supporting data are included in the Supplementary file.
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